Targeting tumour vasculature: the development of combretastatin A4. (Q34572069)

3 August 2017

1 reference

title

Targeting tumour vasculature: the development of combretastatin A4. (English)

1 reference

3 August 2017

J Griggs

1

1 reference

3 August 2017

J C Metcalfe

series ordinal

2

1 reference

3 August 2017

R Hesketh

series ordinal

3

1 reference

3 August 2017

language of work or name

1 reference

1 February 2001

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

2

1 reference

3 August 2017

82-87

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Mechanisms of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Tumor angiogenesis as a predictor of recurrence in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Antiangiogenic strategies and agents in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Antineoplastic agents. 379. Synthesis of phenstatin phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Vasculogenic mimicry and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

Vasculogenic mimicry: how convincing, how novel, and how significant?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900224-2

7 January 2021

10.1016/S1470-2045(00)00224-2

Identifiers

DOI

1 reference

3 August 2017

1 reference